Development of a high yielding E. coli periplasmic expression system for the production of humanized Fab' fragments.

Biotechnol Prog

Discovery Research, Protein Sciences, UCB Pharma, 208 Bath Road, Slough, Berkshire, SL1 3WE, U.K.

Published: January 2017

Humanized Fab' fragments may be produced in the periplasm of Escherichia coli but can be subject to degradation by host cell proteases. In order to increase Fab' yield and reduce proteolysis we developed periplasmic protease deficient strains of E. coli. These strains lacked the protease activity of Tsp, protease III and DegP. High cell density fermentations indicated Tsp deficient strains increased productivity two fold but this increase was accompanied by premature cell lysis soon after the induction of Fab' expression. To overcome the reduction in cell viability we introduced suppressor mutations into the spr gene. The mutations partially restored the wild type phenotype of the cells. Furthermore, we coexpressed a range of periplasmic chaperone proteins with the Fab', DsbC had the most significant impact, increasing humanized Fab' production during high cell density fermentation. When DsbC coexpression was combined with a Tsp deficient spr strain we observed an increase in yield and essentially restored "wild type" cell viability. We achieved a final periplasmic yield of over 2.4g/L (final cell density OD 105), 40 h post Fab' induction with minimal cell lysis.The data suggests that proteolysis, periplasm integrity, protein folding and disulphide bond formation are all potential limiting steps in the production of Fab' fragments in the periplasm of E. coli. In this body of work, we have addressed these limiting steps by utilizing stabilized protease deficient strains and chaperone coexpression. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:212-220, 2017.

Download full-text PDF

Source
http://dx.doi.org/10.1002/btpr.2393DOI Listing

Publication Analysis

Top Keywords

humanized fab'
12
fab' fragments
12
deficient strains
12
cell density
12
fab'
8
cell
8
protease deficient
8
high cell
8
tsp deficient
8
cell viability
8

Similar Publications

Background: Consensus is that immunoglobulin IgG4 contains only N-linked glycosylation. The analysis of several batches of commercial biopharmaceutical product Dupixent using top-down intact mass spectrometry revealed that this IgG4 features a small amount of O-linked glycosylation in the Fab region. This is the first report of an O-linked glycosylation in an IgG4 antibody.

View Article and Find Full Text PDF

High-resolution crystal structure of PD-1 in complex with retifanlimab, the FDA-approved immune checkpoint blocking antibody for treating Merkel cell carcinoma.

Biochem Biophys Res Commun

January 2025

Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029. Republic of Korea, Republic of Korea. Electronic address:

Article Synopsis
  • * The research includes a detailed crystal structure analysis of the PD-1 and retifanlimab complex, revealing how the antibody binds and alters PD-1's conformation to enhance immune interaction.
  • * Understanding the binding mechanism of retifanlimab in relation to other anti-PD-1 antibodies may lead to better strategies for cancer therapies that modulate immune responses.
View Article and Find Full Text PDF

Histidine phosphorylation (pHis) is a non-canonical post-translational modification (PTM) that is historically understudied due to a lack of robust reagents that are required for its investigation, such as high affinity pHis-specific antibodies. Engineering pHis-specific antibodies is very challenging due to the labile nature of the phosphoramidate (P-N) bond and the stringent requirements for selective recognition of the two isoforms, 1-phosphohistidine (1-pHis) and 3-phosphohistidine (3-pHis). Here, we present a strategy for engineering of antibodies for detection of native 3-pHis targets.

View Article and Find Full Text PDF

Fragment crystallizable gamma receptors (FcγRs) mediate various cellular responses with significant cardiovascular implications. They contribute to the anticancer activity of trastuzumab (TRZ), a recombinant humanized monoclonal antibody that interferes with human epidermal growth factor receptor 2 (HER2), thereby blocking its physiological function in cardiac cells. This is responsible for cardiac complications that hamper TRZ clinical application.

View Article and Find Full Text PDF
Article Synopsis
  • Human CD200R1 (hCD200R1) is an immune receptor found mainly on T cells and myeloid cells, and targeting it has shown promise in enhancing anti-tumor activity, particularly with a humanized antibody called 23ME-00610.
  • The study explores how 23ME-00610 blocks hCD200R1's immune checkpoint function by preventing its interaction with another molecule (CD200) through steric hindrance, while also creating a new antibody variant (23ME-00611) that binds effectively to the non-human equivalent (MfCD200R1) for preclinical studies.
  • This research not only sheds light on the molecular mechanics of hCD200R1 blockade but also
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!